Therma Bright Inc.
Therma Bright Inc.
- ISIN: CA8834261080
- Land: .
Nachricht vom 11.10.2018 | 14:54
Therma Bright Engages Top Virology Research Group to Conduct Further Tests of TherOZap(TM) Technology Against the Zika Virus
DGAP-News: Therma Bright Inc. / Key word(s): Miscellaneous
Toronto, Ontario--(Newsfile Corp. - October 11, 2018) - Therma Bright Inc. (TSXV: THRM), ('Therma Bright' or the 'Company'), a progressive medical device technology company announces, further to its press release on January 8, 2018 outlining results indicating effectiveness of its TherOZap™ technology at inhibiting the Zika virus, that the Company has engaged a top research laboratory made up of virology experts to further test the TherOZap™ technology against the Zika virus. The research group collaborates with and has access to other virology research experts around the world.
Further to the Company's press release on October 1st, 2018, the Company has completed several improvements to the TherOZap™ technology prototype including certain advancements to the technology and features that make the prototype easier to use and test by researchers compared to the previous version. The Company expects the receipt of final prototypes over the next 10 days at which time the prototypes will be sent to the researchers to initiate the next round of testing. Testing is expected to last several months.
The Company will follow up with additional testing, providing efficacy of the TherOZap™ technology during the initial tests against the Zika virus, with further in-vitro testing of the Zika virus or other mosquito borne diseases to be followed up by in-vivo testing if warranted.
The Dengue, Zika and West Nile viruses are spread by the same mosquito which is known as the Aedes Aegypti mosquito. The Aedes Aegypti mosquito is known as a prolific daytime biter which often makes it harder for people to protect themselves after an infectious bite. Therma Bright hopes to prove that the TherOZap™ technology will be effective as a second line of defense, after being bitten by a mosquito, against the Zika virus. Once the TherOZap™ technology proves effective, the Company expects to extend the prototype improvements to Therma Bright's final commercial device with an aim to market any claims as a result of successful testing on packaging and marketing material with appropriate regulatory approval.
Mr. Rob Fia, CEO, commented:
'Therma Bright searched diligently and is pleased to have selected this collection of top virology researchers to continue testing our patent pending TherOZap™ technology against the Zika virus. We are excited to report back to our shareholders as testing results are received and we hope to prove the Zika virus is susceptible to die-off with the use of our TherOZap™ technology.'
About Therma Bright Inc.:
Therma Bright is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs. Clear and healthy skin for all is at the core of the Company's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments. The Company's breakthrough proprietary technology delivers effective, non-invasive and pain free skin care.
Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). The Company received approval for the above claims from FDA (United States) in 1997.
For further information please contact:
FORWARD LOOKING STATEMENTS
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES
Click on, or paste the following link into your web browser, to view the associated documents http://www.newsfilecorp.com/release/40305
|Company:||Therma Bright Inc.|
|End of News||DGAP News Service|
UniDevice AG: Rekord-Ergebnis in 2018
Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.
Der AKTIONÄR News
23. Februar 21:52 Breaking: Roche vor Übernahme von Gentherapie-Player Spark ...
23. Februar 13:46 Borussia Dortmund: Endspiel am Sonntag, Zahlen in Line, Aktie ...
23. Februar 10:07 Das perfekte Biotech-Investment: Ein Investment, sechs Chancen (Teil ...
23. Februar 09:43 Amazon, Axon, Walt Disney, Adidas und Co: So geht es weiter
23. Februar 08:53 Österreichische Post: Besser als die Deutsche Post?
News im Fokus
Linde plc: Linde plc Investor & Media Conference Call - Information
22. Februar 2019, 19:38
Vorläufige Geschäftszahlen 2018
26. Februar 2019
Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy
21. Februar 2019